A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome.
Gustavo Luiz Behrens PintoRenata Casseb de Souza CarboniFernando Henrique Carlos de SouzaSamuel Katsuyuki ShinjoPublished in: Clinical rheumatology (2020)
Our study demonstrated that patients with ASS have increased serum levels of the IL-17A compared with healthy controls. In addition, the patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A. Key Points • Patients with ASS have increased serum levels of the IL-17A. • Patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A.